Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There is a pothole in the road
What happens to its life
When it is filled in
ACIP’s RSV votes today (all unanimous):
• RSV vaccination recommended unconditionally for adults age 75+.
• RSV vaccination recommended for adults age 60-74 who have one of the following conditions: lung disease, cardiovascular disease, moderate or severe immunocompromise, diabetes with end organ damage, severe obesity, neurological or neuromuscular conditions, advanced chronic kidney disease, liver disorder, or blood disorders.
• No recommendation at this time that adults age 50-59 should get GSK’s Arexvy, despite the fact that the FDA recently approved Arexvy for age 50-59 (#msg-174567339).
ACIP did not recommended any change to the existing CDC guidance that individuals should seek a “shared” decision with their healthcare provider on whether to get vaccinated for RSV. Hence, adults age 60-74 who do not fit into the third bullet item above remain in “shared decision” limbo, at least for now.
Also, ACIP did not make any recommendation on whether—or when—people should receive a second RSV vaccination.
https://www.statnews.com/2024/06/26/cdc-rsv-acip-hearing/
MRNA is -11% today, validating the (admittedly obvious) thesis in #msg-173915209.
Marking CMV Awareness Month in June
https://www.modernatx.com/en-US/media-center/all-media/blogs/marking-CMV-awareness-month
Nobody...it is, a little gem
How is that related to MRNA? Thanks.
Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial
https://finance.yahoo.com/news/anixa-biosciences-treats-sixth-patient-124500561.html
USDA finds unusual twist: Bird flu moved from dairy cows to poultry in Michigan
https://www.toledoblade.com/business/agriculture/2024/06/23/usda-finds-unusual-twist-bird-flu-h5n1-dairy-cows-poultry-michigan-epidemiology/stories/20240623023
Australia's largest outbreak of bird flu has hit a grim milestone, with Victorian authorities confirming more than 1 million birds will be killed to try and prevent the spread of the virus.
https://www.abc.net.au/news/rural/2024-06-18/bird-flu-outbreak-victoria-one-million-birds-to-be-killed/103991340
Second rule- Know from where it comes
How can one flush
An unknown toxin
When it hasn't been identified
Each toxin
Has its own rule
Like venoms
Across the spectrum
Where did toxins
Come from
In brain
What put it there
FDA selected Moderna's potential treatment for methylmalonic acidemia for its pilot program, Support of Clinical Trials Advancing Rare Disease Therapeutics, or START. The program aims to advance treatments for rare diseases. Methylmalonic acidemia is a rare, genetic disease that prevents the body from breaking down proteins and fats.
Moderna confirmed it's in discussions with the U.S. government to move forward with its bird flu vaccine.
first rule- flush toxins from brain....
Those toxin free
Have the healthiest immune systems
Not having to fight on so many fronts
Has its advantages
it originated in your brain.....long live the pussy
Thailand beat avian flu 20 years ago. What can we learn from their strategies?
62 million.
That’s the number seared in Prasert Auewarakul’s memory. It is the number of birds – mostly chickens – that were dead by the end of Thailand’s avian flu outbreak that started in late 2003. Some died of the disease, others were culled to prevent the virus from spreading.
Now, two decades later, the U.S. is grappling with its own avian flu outbreak. And this time the virus has taken a new twist.
https://www.npr.org/sections/goats-and-soda/2024/06/12/g-s1-4091/avian-flu-cows-chickens-thailand-biosecurity
Seriously
How was it confirmed
Take it from there
Confirmed case of highly contagious avian flu detected in NSW farm
A poultry egg farm has gone into immediate lock down after a case of the highly contagious bird flu was detected in a second state.
https://www.news.com.au/technology/science/animals/confirmed-case-of-highly-contagious-avian-flu-detected-in-nsw-farm/news-story/4d603e07128a8941c79bc0c215911f04
https://www.aphis.usda.gov/sites/default/files/hpai-h5n1-dairy-cattle-mi-epi-invest.pdf
Must be very scared
For it to work
It's all about
Making people sick
How Scared Should You Be of Bird Flu-
https://www.nytimes.com/2024/06/19/opinion/bird-flu-public-risk.html
There is an element of control
When the fear card
Is played
With the threat of H5N1 bird flu, hospitals must stay prepared
https://www.statnews.com/2024/06/18/h5n1-bird-flu-hospitals-should-prepare-now-experts-say/
Bird flu infects seventh Iowa dairy farm, state agency says
https://eu.desmoinesregister.com/story/money/agriculture/2024/06/17/bird-flu-pandemic-iowa-seventh-dairy-farm-infected-sioux-county/74129029007/
Nearly 75% of patients that received the experimental vaccine Moderna and Merck developed, along with Keytruda, were alive without any signs or symptoms of their cancer returning after two and a half years. The overall survival rate of those patients who received the combined treatment that Moderna and Merck developed was 96% after the two-and-a-half-year period. Moreover, Merck and Moderna are expanding the scope of their trial by testing their combined treatment in patients diagnosed with a type of lung cancer.
U.S. faces mounting criticism over bird flu response
https://www.axios.com/2024/06/18/bird-flu-2024-us-response-criticism
What is there to understand
~~~ Book or street ~~~
(13:02)
Focus is key
If it is to be
Moderna announced that it’s flu/Covid vaccine combo completed Phase 3 of its clinical trials and that the vaccine results in a “higher immune response than the licensed comparator vaccines used in the trial.” Were they less likely to contract Covid or the flu? That wasn’t tested. Were they less likely to show symptoms? That also was not tested. Is it safe? Moderna says that it “showed an acceptable tolerability and safety profile.” Acceptable? Let's review that, shall we?
How worried should everyone be
Enough to inject oneself
With a poison
What about the killing of livestock
Through a process called
Gaslighting
Former CDC director predicts bird flu pandemic
“I really do think it’s very likely that we will, at some time, it’s not a question of if, it’s more of a question of when we will have a bird flu pandemic,” Redfield said.
https://thehill.com/policy/healthcare/4723753-former-cdc-director-predicts-bird-flu-pandemic/
All must now fear milk
Go figure
Pasteurization does not necessarily kill H5N1 from milk samples.
Data published today
https://www.nejm.org/doi/full/10.1056/NEJMc2405488
A North Carolina doctor was left paralysed after contracting COVID and 'made peace' that he wouldn't survive the rare syndrome, but was able to make an incredible recovery and return to work in the hospital that
https://www.mirror.co.uk/news/us-news/doctor-left-paralysed-having-made-33030014#google_vignette
Canadian woman sues Moderna for $45 Million
~~~ How many more will follow ~~~
(1:05:13)
Timing is everything
Class actions on the horizon
Kayla Pollock was left paralyzed from the neck down after her third Moderna shot. Doctors have confirmed that her injury was caused by the vaccine. She is the first person in North America to sue a mRNA manufacturer for a vaccine injury.
Why Moderna Stock Is a No-Brainer Buy Right Now
What about valuation..
Perhaps the main argument against Moderna is its valuation. Using projected sales for this year, the stock trades at a price-to-sales ratio of 14.8. The average price-to-sales multiple for the biotech industry is around 6.4.
I don't think the valuation is unreasonable, though, for one simple reason: The company is poised for tremendous growth. Its RSV vaccine should be a slam-dunk commercial success. In my view, Moderna has a good chance of winning approvals over the next few years for many, if not all, of its late-stage programs.
https://www.fool.com/investing/2024/06/10/why-moderna-stock-is-a-no-brainer-buy-right-now/
FROM Spock:
in the int melanoma clinical trial, there were 107 patients in the int plus Keytruda arm.
Of those, 4 died after 3 years. Using the numbers in the Keytruda alone arm, without int, 10 people would have died, so int saved the lives of 6 people.
Also, in the int plus keytruda arm, 11 of the 107 patients developed distant metastasis. Without int, 16 more patients would have developed distant metastasis, so int saved 16 people from having a distant metastasis.
Also, in the int plus keytruda arm, 25 of the 107 patients had a recurrence. Without int, 34 more people would have had a recurrence, so int saved 34 people from having a recurrence.
How on earth can you say that you "cannot make any prediction on the amount of benefit or lack of benefit of Moderna product"?
Seriously
An outbreak
Who will come to the rescue
Oh, knew it was coming
Have the remedy
Come get it
Followers
|
175
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
13522
|
Created
|
12/10/18
|
Type
|
Free
|
Moderators DewDiligence Vexari axelvento |
2021 was a year of monumental impact and change for Moderna
Moderna entered 2021 with a strong cash position of approximately $5.25 billion. We have used this capital to invest in R&D and scale our development pipeline and manufacturing capabilities to maximize our impact on human health.
As we close our books for 2021, the company’s cash, cash equivalents and investments as of December 31, 2021, were more than $17 billion. We now have the resources to scale our investments and do even more to positively impact human health with mRNA medicines. This is just the beginning.
.
https://www.modernatx.com/newsroom/our-blog-coding-region/moderna-2021-shareholder-letter
Moderna is entering 2022 with a remarkable team poised to continue advancing mRNA vaccines and therapeutics into new areas for patients. We have a clear and exciting strategic path to do so, and a strong cash position.
Priority two is to go after the most important latent viruses and develop first-in-class vaccines against them. We want to protect our fellow human beings from suffering from the long-term damage caused by these viruses. Too many people have the quality of their health impacted because decades before, they were infected with a latent virus. We envision a world where vaccines against all the most important latent viruses are available to all.
Priority three is to bring to market therapeutics based on mRNA-encoded proteins, like our current pipeline in oncology, cardiology, rare genetic diseases and autoimmune diseases.
Priority four is to bring to market innovative therapeutics based on mRNA-encoded gene editing enzymes.
Moderna expects to enroll approximately 34,000 participants in multiple countries
RSV is a leading cause of severe respiratory illness in older adults (65+) and young children; there is no approved vaccine to prevent RSV
RSV illness in older adults results in an estimated $3 billion in annual medical costs in the U.S. each year
NOVEMBER, 18, 2021
https://investors.modernatx.com/news/news-details/2021/Moderna-Announces-First-Participant-Dosed-in-Phase-2-3-Study-of-its-mRNA-Respiratory-Syncytial-Virus-RSV-Vaccine/default.aspx
MODERNA ANNOUNCES POSITIVE DATA FROM PHASE 2 STUDY OF MRNA VEGF-A THERAPEUTIC IN PATIENTS UNDERGOING CORONARY ARTERY BYPASS GRAFTING SURGERY
Approval based on a comprehensive submission package including efficacy and safety data approximately six months after second dose
SPIKEVAX has received approval by regulators in more than 70 countries, including Canada, Japan, the European Union, the UK, Israel
807 million doses of Moderna's COVID-19 vaccine shipped globally in 2021; approximately 25% of those doses shipped to low- and middle-income countries
https://investors.modernatx.com/news/news-details/2022/Moderna-Receives-Full-U.S.-FDA-Approval-for-COVID-19-Vaccine-Spikevax/default.aspx
Q4 2021 revenues of $7.2 billion; GAAP net-income of $4.9 billion and GAAP diluted EPS of $11.29
Full year 2021 revenues of $18.5 billion; GAAP net-income of $12.2 billion and GAAP diluted EPS of $28.29
Moderna increased its 2022 signed advance purchase agreements to approximately $19 billion, with additional signed options of approximately $3 billion; numerous discussions ongoing with governments for the fall of 2022 and 2023
Moderna received full U.S. FDA approval for COVID-19 vaccine, Spikevax
Moderna announces new bivalent booster candidate (mRNA-1273.214) combining Omicron-specific booster candidate (mRNA-1273.529) and the Moderna COVID-19 vaccine (mRNA-1273)
Company now has 44 programs in development
Moderna announces a new $3 billion share repurchase plan
https://investors.modernatx.com/news/news-details/2022/Moderna-Reports-Fourth-Quarter-and-Fiscal-Year-2021-Financial-Results-and-Provides-Business-Updates/default.aspx
Facility to manufacture drug substance with opportunity for fill/finish and packaging capabilities
Moderna investing up to $500 million to produce up to 500 million doses each year for the African continent
Moderna will invest in building mRNA capabilities in Africa
https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-Memorandum-of-Understanding-with-the-Government-of-the-Republic-of-Kenya-to-Establish-its-First-mRNA-Manufacturing-Facility-in-Africa/default.aspx
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |